Pharmaceuticals

M&A Roundup 2024: Q&A with Subin Baral

bexib
By bexib 0 Min Read

EY Global Life Sciences deals leaders discuss how the first half of 2024 performed compared to a strong end to 2023.

You Might Also Like

Independence Blue Cross and Benefit Data Trust Partner to Increase Participation in Public Benefit Programs

Does the pharmaceutical company’s blockbuster immunotherapy work for dogs?

FDA approves AstraZeneca’s Imfinzi in combination with chemotherapy for resectable early-stage non-small cell lung cancer

Avicenna.AI receives EU certification for its AI imaging products

As layoffs continue and employees become paralyzed by fear of their jobs in 2024, how can leaders address critical real-world issues?

Share This Article
Previous Article Survey shows most retail brands are ignoring X
Next Article Review: AnyCubic Kobra 3 – Manufacturer:
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

In preparation. Introducing a week-long culinary collaboration to raise money for children’s food education
Hospitality & Tourism
Listen: Top 3 Bank Automation News Podcasts of 2024
Banking
What is precision agriculture and how does it work?
Agro Businesses
Opening Facebook shop in 2025
Retail & E-commerce